Inflation Reduction Act May Accelerate Generic And Biosimilar Market Entry, But Questions Remain Around CMS Guidance

The IRA may alter the incentives drug firms have to pursue evergreening strategies, as having generic or biosimilar competition can exempt a drug from price negotiation.

Source: Forbes.com Healthcare News - September 5, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news